Hantavirus Tracker

The dominant theme is stepped-up preparedness and emergent countermeasures against Andes hantavirus: PAHO’s regional workshop boosted surveillance, diagnostics, sequencing and One Health outbreak response across 12 countries, while UTMB reported a single‑dose mRNA vaccine that fully protected hamsters and is being fast‑tracked toward human trials.

The items converge on the need for rapid detection and cross‑jurisdictional coordination, but expose a tension between promising preclinical vaccines and immediate operational priorities — rigorous PCR confirmation to avoid false positives, continued contact tracing/observation, and clinical readiness (including ECMO biocontainment).

Watch for human‑trial moves and expanded genomic surveillance.

Tracking: hantavirus

1. PAHO strengthens regional hantavirus surveillance at Panama workshop

PAHO concluded a four-day regional workshop in Santiago del Este, Panama (June 1–4, 2026) to strengthen surveillance, diagnosis, and response capacities for hantavirus and other viral hemorrhagic fevers.

Fifty-five specialists from 12 countries participated, focusing on molecular and serological testing, genomic sequencing, and hands-on outbreak exercises integrating epidemiology, laboratory, and ecological surveillance.

The activity followed PAHO’s December 2025 epidemiological alert and recent regional increases in cases, including a cruise ship–associated transmission event in April 2026.

Partners including the Gorgas Memorial Institute, Argentina’s INEI-ANLIS Malbrán institutes, and the CDC ran a tabletop outbreak investigation exercise and emphasized One Health coordination among health, laboratory, and animal control teams.

Key facts:

- Workshop held June 1–4, 2026, in Santiago del Este, Panama.

- 55 specialists from 12 countries participated.

- PAHO issued an epidemiological alert in December 2025.

- 2025: 229 confirmed cases and 59 deaths in eight countries.

- Through mid‑April 2026: 94 cases and 13 deaths in six countries.

Why it matters: Strengthened laboratory capability and One Health coordination should accelerate detection and response, benefiting national public-health systems and aiding quicker identification of travel-related exposures.

Monitor genomic sequencing outputs, regional case counts, and implementation of integrated surveillance, particularly in tourism settings and rodent-control operations.

Paho

2. Single-dose mRNA vaccine fully protects hamsters against Andes hantavirus

Last month’s Andes virus outbreak on a Dutch cruise ship departing Argentina infected 13 people, killed three, and dispersed passengers to 23 countries, underscoring the virus’ unique person-to-person risk and the absence of approved vaccines or preventive treatments.

Researchers at the University of Texas Medical Branch report in The Lancet that a single-dose mRNA vaccine encoding hantavirus envelope glycoproteins Gn and Gc delivered 100% protection against a lethal Andes virus challenge in Syrian hamsters.

The vaccine produced protective antibodies in as little as 14 days and prevented infection even at substantially reduced doses; vaccinated animals showed "no symptoms or weight loss."

The team previously showed two-dose efficacy and retested because outbreaks do not allow weeks between shots.

UTMB’s Alexander Bukreyev said the group is working to fast-track single-dose candidates into human trials, and investigators propose rapid post-exposure use for high-risk contacts.

Key facts:

- 13 people infected and three deaths on the cruise ship outbreak last month

- Passengers returned to 23 countries after the outbreak

- No approved vaccines or preventive treatments currently exist for Andes virus

- Single-dose mRNA vaccine gave 100% protection in Syrian hamsters

- Protective antibodies detected in as little as 14 days

Why it matters: A single-shot, fast-acting vaccine could change outbreak response: it may enable rapid post-exposure vaccination of high-risk contacts and shorten containment timelines.

Public-health agencies, clinical trial sponsors, and regulators stand to benefit from a one-dose regimen that protects quickly; researchers must now validate safety and efficacy in humans.

Watch for initiation and design of human trials, regulatory engagement, and whether supply and deployment logistics prioritize post-exposure use during future Andes virus events.

Genengnews

3. San Quentin suspected hantavirus case ruled false positive

1 suspected hantavirus case at San Quentin Rehabilitation Center was ruled a false positive after PCR testing.

California Department of Public Health, the Department of Corrections and Rehabilitation and Marin County Public Health investigated after a commercial laboratory reported a positive antibody test; CDPH’s Viral and Rickettsial Diseases Laboratory performed PCR on a new sample that was negative and concluded this is not a hantavirus case, with additional specialized testing to be repeated at the Centers for Disease Control and Prevention.

The inmate remained in stable condition, no quarantine was issued, and the housing area was decontaminated as a precaution. Antibody tests can cross-react with other viral infections, making false positives common, officials said.

Recent attention on the Andes strain — implicated in a cruise ship outbreak and capable of human-to-human spread — and the disease’s rarity (890 U.S. laboratory-confirmed cases since 1993) underline why authorities prioritize confirmatory PCR testing and monitoring.

Key facts:

- 1 suspected hantavirus case at San Quentin ruled a false positive.

- Commercial laboratory reported a positive antibody test initially.

- CDPH Viral and Rickettsial Diseases Laboratory PCR on a new sample was negative.

- CDPH determined this is not a hantavirus case; sample sent to CDC for repeat testing.

- Housing area decontaminated; no quarantine issued; inmate remained stable.

Why it matters: False-positive antibody results can prompt intensive, costly interventions—decontamination and population monitoring at facilities designed for over 3,000 inmates—demonstrating the operational burden of preliminary lab signals.

Given hantavirus’s lack of vaccine or specific antiviral therapy and the recent Andes outbreak with human-to-human transmission, authorities must rely on confirmatory PCR and CDC verification; watch for CDC results and any PCR-positive cases that would change containment needs.

Abc7newsLatimes

4. Three Kansans complete 42-day hantavirus observation period

Three Kansans completed a 42-day observation period on June 7 after high-risk exposure to a person with confirmed Andes hantavirus following an outbreak aboard the MV Hondius cruise ship.

The exposed individuals shared an international flight with a symptomatic passenger who later tested positive and died; they were hospitalized at the University of Kansas Hospital, discharged May 21, and remained asymptomatic while voluntarily isolating.

The Kansas Department of Health and Environment reports no confirmed cases in the state and characterizes the public risk as "extremely low."

Because the Andes virus can spread person-to-person and has no treatment, continued cross-jurisdictional contact tracing and readiness for extracorporeal membrane oxygenation (ECMO) biocontainment remain priorities.

Key facts:

- 3 Kansans completed a 42-day observation period on June 7.

- No confirmed Andes hantavirus cases in Kansas to date.

- Exposure occurred on an international flight after MV Hondius cruise outbreak.

- Exposed trio hospitalized, then discharged May 21.

- Governor Laura Kelly declared a disaster emergency on May 12.

Why it matters: Completing observation reduces the near-term likelihood Kansas must use biocontainment transport and ECMO capacity reserved under the emergency declaration.

However, Andes' person-to-person transmission and lack of treatment mean travel-linked clusters can still demand high-level clinical resources; watch for additional cases tied to the MV Hondius or shared flights and maintain contact-tracing and biocontainment readiness.

Cjonline